ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag biotech fda cancer disease medicine

The Breakthrough Prize ?Trophy
2024 Breakthrough Prizes in Life Sciences
Danielle Gerhard, PhD | Sep 14, 2023 | 10 min read
This year’s Breakthrough Prizes honor advances in CAR T cancer therapies, cystic fibrosis, and Parkinson’s disease.
The Vaginal Microbiome is Finally Getting Recognized
Hannah Thomasy, PhD, Drug Discovery News | Sep 25, 2023 | 10+ min read
Vaginal dysbiosis has long been a taboo subject, but studying and optimizing the vaginal microbiome could be a game changer for women's health.
A vet and technician take a sample from a dog for use in PetDx’s OncoK9 test, which screens cell-free DNA for genomic alterations associated with cancer.
The Pet Health Industry Takes on Canine Cancer
Diana Kwon | Oct 17, 2022 | 9 min read
Advanced genomic tools have provided biotech companies new approaches to help our furry friends—but experts say several limitations remain.
The Little Cell That Could
Megan Scudellari | Jul 1, 2012 | 7 min read
Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.
2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
Biotech's Baddies
Bob Grant | Apr 1, 2009 | 10+ min read
Biotech's Baddies More than 60 individuals have been blackballed by the FDA for criminal acts against the agency. Here are some of the worst offenders. By Bob Grant ©Tim Kiusalaas o matter how bad things seem for the United States Food and Drug Administration these days, 20 years ago they were arguably worse. In the late 1980s, the agency was embroiled in a generic-drug scandal, in which FDA administrators accepted bribes fo
FDA Approves Gene Therapy for Spinal Muscular Atrophy
Ashley Yeager | May 27, 2019 | 3 min read
At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.
Lazarus Drugs
Kate Yandell | Feb 1, 2015 | 8 min read
While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.
 
Top 10 Innovations 2021
2021 Top 10 Innovations
The Scientist | Dec 1, 2021 | 10+ min read
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
FDA Rewrites Rules on Biologics
Susan Warner | Jul 27, 2003 | 7 min read
In a move designed to speed approval of new biotech products, the US Food & Drug Administration has transferred oversight for many new biotech therapies from its office that reviews biologics to the one that approves traditional drugs. Biotech and pharmaceutical companies had been pushing for the change for years, because it's generally believed that companies can more easily get regulatory clearance from the drug review section of the agency. This change became a reality with the arriva

Run a Search

ADVERTISEMENT